Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2022 - 2025)

Agios Pharmaceuticals' Other Non-Current Liabilities history spans 7 years, with the latest figure at $90000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 89.77% year-over-year to $90000.0; the TTM value through Dec 2025 reached $90000.0, down 89.77%, while the annual FY2025 figure was $90000.0, 89.77% down from the prior year.
  • Other Non-Current Liabilities reached $90000.0 in Q4 2025 per AGIO's latest filing, roughly flat from $90000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q4 2022 to a low of $90000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 4 years is $1.0 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: grew 9.57% in 2023, then crashed 92.21% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $3.3 million in 2022, then crashed by 64.75% to $1.2 million in 2023, then decreased by 23.88% to $880000.0 in 2024, then plummeted by 89.77% to $90000.0 in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Other Non-Current Liabilities are $90000.0 (Q4 2025), $90000.0 (Q3 2025), and $101000.0 (Q2 2025).